Our Pricing

Wegovy vs Saxenda Side Effects: What UK Clinical Data Shows

Published on: June 03, 2026

Understanding wegovy vs saxenda side effects uk profiles is essential when choosing between these two MHRA-licensed weight loss injections. Both semaglutide (Wegovy) and liraglutide (Saxenda) are GLP-1 receptor agonists with well-documented safety data from large-scale clinical trials, but their side effect frequencies and severity differ significantly. At Cured Pharmacy, our UK-registered clinical team helps patients navigate these differences during their free online consultation.

Most Common Side Effects: Wegovy vs Saxenda UK Data

Gastrointestinal side effects are the most frequently reported adverse events with both medications. In the STEP clinical trial programme for Wegovy, nausea occurred in 44% of participants, diarrhoea in 30%, and vomiting in 24% [1]. The SCALE trials for Saxenda showed similar patterns, with nausea affecting 39% of participants, diarrhoea in 21%, and constipation in 19% [2].

The key difference lies in duration and intensity. Wegovy's once-weekly dosing typically produces side effects that peak within 24-48 hours post-injection and subside before the next dose [1]. Saxenda's daily injection schedule means patients may experience more consistent but often milder gastrointestinal symptoms throughout treatment [2].

Most side effects with both medications are mild to moderate and decrease significantly after the first 8-12 weeks as the body adapts to treatment [1][2]. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) notes that proper dose escalation is critical for minimising these effects—both medications follow structured titration schedules specifically designed to improve tolerability.

Nausea and Vomiting: Comparative Frequency in UK Trials

Nausea represents the most common reason for treatment discontinuation with GLP-1 receptor agonists. In head-to-head comparisons, Wegovy shows a higher initial incidence of nausea (44%) compared to Saxenda (39%), but the severity profile differs [1][2].

Wegovy-related nausea typically occurs within 24-72 hours of injection, peaks during the dose escalation phase, and resolves within 2-3 days in most patients [1]. Saxenda's daily dosing produces more consistent but generally less intense nausea, which patients often describe as persistent mild queasiness rather than acute episodes [2].

Discontinuation rates due to gastrointestinal side effects were 4.3% for Wegovy in STEP trials and 6.2% for Saxenda in SCALE trials, suggesting that whilst Wegovy has higher initial nausea rates, fewer patients ultimately stop treatment because of it [1][2]. Practical management strategies include taking injections before bed, eating smaller meals, and avoiding high-fat foods during the first month of treatment.

Managing Gastrointestinal Side Effects

UK prescribers recommend several evidence-based approaches to minimise nausea with both medications. These include injecting at consistent times (evening for Wegovy to sleep through peak symptoms, morning for Saxenda to avoid bedtime nausea), staying well-hydrated, eating protein-rich meals, and never skipping the gradual dose escalation schedule. If symptoms persist beyond 12 weeks or worsen rather than improve, your prescriber may adjust your dose or consider alternative treatments available at Cured Pharmacy.

Serious Side Effects and Safety Considerations

Both Wegovy and Saxenda carry similar warnings regarding rare but serious adverse events. The MHRA requires monitoring for pancreatitis, gallbladder disease, and thyroid C-cell tumours, though these occur in less than 1% of patients [3][4].

Acute pancreatitis was reported in 0.2% of Wegovy patients and 0.3% of Saxenda patients in clinical trials [1][2]. Symptoms include severe persistent abdominal pain radiating to the back, often accompanied by nausea and vomiting. Both medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [3][4].

Hypoglycaemia risk is low with both medications when used alone for weight management, as GLP-1 receptor agonists work in a glucose-dependent manner [1][2]. However, patients taking concurrent diabetes medications may require dose adjustments. All prescription treatments at Cured Pharmacy require clinical assessment by a UK prescriber who will review your full medical history and current medications to identify any contraindications.

Injection Site Reactions: Wegovy vs Saxenda Side Effects UK

Local injection site reactions occur less frequently than gastrointestinal side effects but remain a consideration for both medications. Wegovy trials reported injection site reactions in 3.4% of participants, whilst Saxenda studies showed a slightly higher rate of 6.8% [1][2].

Saxenda's daily injection schedule inherently increases the total number of injection events, which may explain the higher incidence of localised redness, itching, or mild swelling at injection sites [2]. Wegovy's once-weekly dosing reduces overall injection frequency by approximately 85%, correspondingly lowering the cumulative risk of injection site reactions [1].

Most injection site reactions with both medications are mild, resolve within 24-48 hours, and can be minimised by rotating injection sites systematically between the abdomen, thigh, and upper arm. Persistent or worsening reactions should be reported to your prescriber during follow-up consultations.

Proper Injection Technique

Correct injection technique significantly reduces the risk of site reactions. Both Wegovy and Saxenda should be injected subcutaneously (under the skin, not into muscle) at a 90-degree angle. Allow the medication to reach room temperature before injecting, clean the injection site with an alcohol wipe, and never inject into areas that are tender, bruised, or scarred. Our UK clinical team provides detailed injection training materials with every prescription dispensed from Cured Pharmacy.

Long-Term Tolerability and Treatment Continuation Rates

Treatment adherence data from clinical trials provides insight into real-world tolerability. In the 68-week STEP 1 trial, 81.6% of Wegovy patients completed the full study period [1]. The 56-week SCALE Obesity and Prediabetes trial showed 71.8% of Saxenda patients remained on treatment through completion [2].

The higher continuation rate with Wegovy may reflect its once-weekly convenience factor combined with superior weight loss outcomes (average 14.9% body weight reduction vs 8.0% with Saxenda), which motivates patients to persist through initial side effects [1][2]. However, individual tolerability varies considerably—some patients find Saxenda's daily dosing allows for more precise symptom management.

Long-term safety data spanning up to 2 years shows that most adverse events occur during the dose escalation phase, with new-onset side effects becoming rare after 6 months of stable dosing [3][4]. Both medications have been extensively studied in UK populations and are recommended by NICE for weight management in appropriate patients, subject to prescriber approval.

Which Has Fewer Side Effects: Wegovy or Saxenda?

Neither medication definitively has fewer side effects—the profile depends on individual patient factors and priorities. Wegovy shows higher initial nausea rates (44% vs 39%) but better long-term continuation rates (81.6% vs 71.8%), suggesting patients find the side effects more manageable overall [1][2].

Saxenda's daily dosing may suit patients who prefer consistent, predictable effects and the ability to skip a dose if experiencing symptoms, though this is not recommended without prescriber guidance [2]. Wegovy's once-weekly schedule appeals to those prioritising convenience and willing to manage more intense but time-limited weekly symptoms [1].

At Cured Pharmacy, Wegovy is available from £20 off first order using code WEIGHTLOSSNEW

Starting Your Weight Loss Treatment

Both Wegovy and Saxenda require a structured approach including gradual dose escalation, regular prescriber follow-ups, and lifestyle modifications for optimal results and minimal side effects. Cured Pharmacy's UK-registered clinical team provides ongoing support throughout your treatment journey, with discreet packaging, next-day delivery options, and the lowest prices guaranteed across the UK. Start your free online consultation today—it takes under 3 minutes, and you'll see exact pricing before completing your assessment.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., & Wilding, J. P. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
3. Medicines and Healthcare products Regulatory Agency. (2022). Wegovy 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. GOV.UK. https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency [accessed 13 August 2026]
4. Medicines and Healthcare products Regulatory Agency. (2020). Saxenda 6 mg/ml solution for injection in pre-filled pen: Summary of Product Characteristics. GOV.UK. https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and side effects can differ between patients. If you experience severe or persistent side effects, contact your prescriber or seek immediate medical attention.